SCHEMBL25204192

SCHEMBL25204192

O=C1NCCc2sc(-c3nc(Nc4cc5c(cc4F)CNCC5)ncc3C(F)(F)F)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 1/20 0.40
▸ PTK2 Q05397 2/20 0.38
▸ CDK4 P11802 3/20 0.36
▸ CDK6 Q00534 3/20 0.36
▸ CCNA2 P20248 2/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ CCNT1 O60563 1/20 0.36
▸ CCND1 P24385 1/20 0.36
▸ CCND3 P30281 1/20 0.36
▸ CDK7 P50613 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CCNH P51946 1/20 0.36
▸ MNAT1 P51948 1/20 0.36
▸ PARP1 P09874 2/20 0.36
▸ PARP2 Q9UGN5 2/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ DBF4 Q9UBU7 1/20 0.36
▸ NTRK1 P04629 1/20 0.34
▸ WEE1 P30291 4/20 0.33
▸ PKMYT1 Q99640 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30412493 1.00 MAP4K1 (0.40) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL25208001 0.91 MAP4K1 (0.44) MAP4K1PTK2PARP1PARP2CDC7
SCHEMBL30413194 0.91 MAP4K1 (0.44) MAP4K1PTK2PARP1PARP2CDC7
SCHEMBL30412210 0.90 MAP4K1 (0.40) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL25210979 0.90 MAP4K1 (0.40) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL25220804 0.89 MAP4K1 (0.38) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL30412258 0.89 MAP4K1 (0.40) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL25207999 0.89 MAP4K1 (0.40) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL30412783 0.89 MAP4K1 (0.38) MAP4K1PTK2CDK4CDK6CCNA2
SCHEMBL25233172 0.87 LRRK2 (0.41) MAP4K1PTK2CDK4CDK6CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 MAP4K1 182/4885PTK2 1123/4885CDK4 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback